<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967407</url>
  </required_header>
  <id_info>
    <org_study_id>DE-UKMD-URO-001</org_study_id>
    <secondary_id>DRKS00004266</secondary_id>
    <secondary_id>U1111-1140-0415</secondary_id>
    <secondary_id>DRKS00004266</secondary_id>
    <secondary_id>EUDAMED-No.: CIV-12-04-006021</secondary_id>
    <secondary_id>00020520</secondary_id>
    <nct_id>NCT01967407</nct_id>
  </id_info>
  <brief_title>IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.</brief_title>
  <acronym>IRENE</acronym>
  <official_title>Prospective, Monocentric, Clinical Phase-I/II Study of the Effectiveness of the Percutaneous Irreversible Electroporation (IRE) of Locally Confined Kidney Tumors (Renal Cell Carcinomas).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Magdeburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Magdeburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is the evaluation of the ablation efficiency of the percutaneous
      irreversible electroporation (IRE) as primary ablation therapy of locally confined renal cell
      carcinoma (≤4cm, see inclusion and exclusion criteria).

      The ablation success will be proofed by magnet resonance imaging (MRI) and histologically
      after partial kidney resection or nephrectomy 4 weeks after IRE. Hypotheses: Kidney tumors
      ≤4cm can be ablated completely by percutaneous IRE. Surrounded structures and renal tissue
      can be preserved.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Health Condition or Problem studied:

        1. International Statistical Classification of Diseases and Related Health Problems, Tenth
           Revision (ICD10): C64 - Malignant neoplasm of kidney, except renal pelvis

        2. ICD10: D41.0 - Neoplasm of uncertain or unknown behaviour: Kidney

      Interventions/Observational Groups Arm 1:

        1. Initial diagnostical examination of the renal mass.

        2. If any extended diagnostical examination for treatment planning.

        3. Day -29 to -1: Recruitment.

        4. Day -1: MRI of the kidney, Karnofsky, physical examination, blood chemistry,
           urosonography, if any renal scintigraphy, life quality assessment.

        5. Day 0: Percutaneous diagnostical biopsy with histopathological investigation and
           therapeutically, CT- and/or ultrasound-guided, ECG-synchronized irreversible
           electroporation (IRE) of the kidney tumor in endotracheal anaesthesia und muscle
           relaxation. Use of 1-6 IRE probes with 90-100 pulses of 1500-3000 volts und 20-50
           amperes each.

        6. Day 1-7: Postinterventional follow-up: MRI of the kidneys, Karnofsky, physical
           examination, blood chemistry, urosonography, life quality assessment.

        7. Day 27: Postinterventional follow-up: MRI of the kidneys, Karnofsky, physical
           examination, blood chemistry, urosonography, if any renal scintigraphy, life quality
           assessment.

        8. Day 28: Open surgery partial kidney resection or tumor nephrectomy of the IRE treated
           kidney resp. kidney tumor region with histopathological investigation.

        9. Day 29-37: Postoperative follow-up: physical examination, blood chemistry,
           urosonography, life quality assessment.

       10. Day 112: Study-Follow-up: MRI of the kidneys, Karnofsky, physical examination, blood
           chemistry, urosonography, if any renal scintigraphy, life quality assessment.
           Termination of the study.

       11. Study closed, Individual follow-up due to the European Association of Urology guideline.

      Recruitment:

        -  (Anticipated or Actual) Date of First Enrollment: 2013/10/14

        -  Planned/Actual: Opened

        -  Target Sample Size: 20

        -  Monocentric/Multicentric trial: Monocentric trial

        -  National/International: National
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>analysis of ablation effectiveness of non-metastatic renal tumors &lt;4cm 28 days by after irreversible electroporation (NanoKnife, AngioDynamics Inc.) by histopathological examination of partial kidney resection specimens</measure>
    <time_frame>28 days</time_frame>
    <description>onco-therapeutic effectiveness, measured against persistent active tumor / cancer cells by histopathological and magnet resonance imaging analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>4 month</time_frame>
    <description>adverse effects
Assessment of the procedural compliance
Assessment of the Quality of Life (QoL)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Kidney Tumor</condition>
  <condition>Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>renal tumor &lt;4cm, suspected RCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention/ Time point: Irreversible Electroporation at day 0 of each patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Irreversible Electroporation (IRE)</intervention_name>
    <description>Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.</description>
    <arm_group_label>renal tumor &lt;4cm, suspected RCC</arm_group_label>
    <other_name>NanoKnife (Tissue Ablation) System, AngioDynamics Inc.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  one or more localized, resectable kidney tumors (≤4 cm) suspicious of malignancy or
             histology -proven renal cell cancer (RCC)

          -  patients desire for therapy and surgical therapy

          -  Karnofsky-index &gt;70%

          -  Age ≥ 18 years

          -  life expectancy ≥ 12 month

          -  compliance of the patient taking part in a study

          -  informed consent

        Exclusion Criteria:

          -  violation against one or more inclusion criteria

          -  cardial pacemaker or other electrical implants

          -  QT-interval &gt;550 ms or cardiac arrhythmias or condition after myocardial infarction,
             that make an ECG-synchronisation unfeasible

          -  known cardial ejection fraction &lt; 30% or NYHA III or III-IV

          -  known epilepsy

          -  second malignancy (except basal-cell carcinoma and cervical carcinoma in situ)

          -  immunosuppression or HIV-positive patients

          -  active infection or severe health interference, that make taking part in a study
             unfeasible

          -  pregnancy, lactation period, no contraception

          -  metastatic disease

          -  palliative status

          -  running or executed RCC therapy

          -  taking part in another clinical study for RCC

          -  inoperable

          -  rejection of interventional or surgical therapy by the patient

          -  circulatory instability

          -  general contraindications for anesthesia, endotracheal anesthesia and muscle
             relaxation

          -  psychiatric disorders that make taking part in a study or giving informed consent
             unfeasible

          -  haemorrhage, impossible intermission of taking blood thinner, untreatable
             thrombophilia

          -  thromboplastin time ≤50 %, thrombocytes ≤50 Gpt/L; partial thromboplastin time &gt;50

          -  MRI incompatibility

          -  metal implants &lt;1 cm closed to the kidney / kidney tumor

          -  contraindication for biopsy and punction of the renal tumor under CT-guidance

          -  untreated urinary retention

          -  renal pelvis tumor, suspected transitional cell cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe- B. Liehr, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, University Magdeburg, Germany.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Schostak, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Urology, University Magdeburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johann J. Wendler, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, University Magdeburg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antje Wiede, Dr.</last_name>
    <phone>+493916721841</phone>
    <email>antje.wiede@med.ovgu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johann J. Wendler, Dr. med.</last_name>
    <phone>+493916715036</phone>
    <email>johann.wendler@med.ovgu.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pathology University Hospital Otto-von-Guericke-University Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sandra Böttcher, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albert Roessner, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiology University Hospital Otto-von-Guericke-University Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jens Ricke, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Fischbach, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maciej Pech, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Jürgens</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Urology University Hospital Otto-von-Guericke-University Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Markus Porsch, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Janitzky, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Baumunk, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Schindele, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon Blaschke</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MVZ Hanse Histologikum GmbH Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22547</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Köllermann, PD Dr. med.</last_name>
      <phone>0049-40-707085200</phone>
      <email>koellermann@pathologie-hh.de</email>
    </contact>
    <investigator>
      <last_name>Jens Köllermann, PD Dr. med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://urologie.med.uni-magdeburg.de/urologie.html</url>
    <description>Department of Urology, University Magdeburg</description>
  </link>
  <link>
    <url>https://drks-neu.uniklinik-freiburg.de/drks_web/navigate.do?navigationId=start&amp;messageDE=Home&amp;messageEN=Home</url>
    <description>German Clinical Trials Register (DRKS)</description>
  </link>
  <reference>
    <citation>Liehr UB, Wendler JJ, Blaschke S, Porsch M, Janitzky A, Baumunk D, Pech M, Fischbach F, Schindele D, Grube C, Ricke J, Schostak M. [Irreversible electroporation: the new generation of local ablation techniques for renal cell carcinoma]. Urologe A. 2012 Dec;51(12):1728-34. doi: 10.1007/s00120-012-3038-8. German.</citation>
    <PMID>23139026</PMID>
  </reference>
  <reference>
    <citation>Jiang C, Davalos RV, Bischof JC. A review of basic to clinical studies of irreversible electroporation therapy. IEEE Trans Biomed Eng. 2015 Jan;62(1):4-20. Review.</citation>
    <PMID>25389236</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2013</study_first_submitted>
  <study_first_submitted_qc>October 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2013</study_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Magdeburg</investigator_affiliation>
    <investigator_full_name>Johann J. Wendler, MD</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>kidney tumor</keyword>
  <keyword>renal cell cancer</keyword>
  <keyword>RCC</keyword>
  <keyword>irreversible electroporation</keyword>
  <keyword>IRE</keyword>
  <keyword>partial kidney resection</keyword>
  <keyword>percutaneous</keyword>
  <keyword>ablation</keyword>
  <keyword>IRENE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 9, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

